Neuroblastoma

UCSF Protocol No. ClinicalTrials.gov Protocol No. PI Name Title
 Pediatric Cancers > Neuroblastoma
5161 NCT01370330 Vo, Kieuhoa 131-I-Metaiodobenzylguanidine (131-I-MIBG) Therapy for Refractory Neuroblastoma and Related Tumors
14083 NCT02124772 Mueller, Sabine An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations
16087 NCT03561259 Vo, Kieuhoa A Phase II Single-arm Study of Therapeutic Iobenguane (131-I) for Relapsed, High-risk Neuroblastoma Subjects
190817 NCT04106219 Vo, Kieuhoa A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
ANBL1232 NCT02176967 Rangaswami, Arun Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
ANBL1531 NCT03126916 Vo, Kieuhoa A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
ANBL1821 NCT03794349 Rangaswami, Arun A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma
NANT-2013-01 NCT02573896 Vo, Kieuhoa A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma with Dinutuximab +/- Lenalidomide
NANT-2015-01 NCT02868268 Vo, Kieuhoa N2015-01: Neuroblastoma Precision Trial
NANT-2015-02 NCT03107988 Vo, Kieuhoa PHASE 1 STUDY OF LORLATINIB (PF-06463922), AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH ALK-DRIVEN RELAPSED OR REFRACTORY NEUROBLASTOMA
NANT-2017-01 NCT03332667 Vo, Kieuhoa A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory Neuroblastoma
 Pediatric Cancers > Rare Tumors
150814 NCT02520713 Sabnis, Amit Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Solid Tumors: The iCat2, GAIN Consortium Study
150816 NCT02601937 Vo, Kieuhoa A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
ADVL1622 NCT02867592 Vo, Kieuhoa Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
ADVL1823 NCT03834961 Vo, Kieuhoa Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
 Pediatric Cancers > Phase 1 Clinical Trials
16081 NCT02650401 Sabnis, Amit A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS WITH LOCALLY ADVANCED OR METASTATIC SOLID OR PRIMARY CNS TUMORS AND/OR WHO HAVE NO SATISFACTORY TREATMENT OPTION
19082 NCT03654716 Vo, Kieuhoa Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
 Pediatric Cancers > Relapsed/Refractory Pediatric Tumors 
150816 NCT02601937 Vo, Kieuhoa A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
160825 NCT03690869 Mueller, Sabine A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
160829 NCT02909777 Vo, Kieuhoa Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
ADVL1414 NCT02323880 Vo, Kieuhoa A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
ADVL1514 NCT02975882 Vo, Kieuhoa  A Phase 1 Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
ADVL1614 NCT03320330 Vo, Kieuhoa A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
ADVL1615 NCT03323034 Vo, Kieuhoa A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
ADVL1711 NCT03245151 Vo, Kieuhoa A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
ADVL1921 NCT03709680 Vo, Kieuhoa PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
APEC1621A NCT03213704 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
APEC1621B NCT03210714 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493  (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations
APEC1621C NCT03213665 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
APEC1621D NCT03213678 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors
APEC1621E    NCT03213691 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
APEC1621F NCT03213652 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
APEC1621G NCT03220035 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations
APEC1621H NCT03233204 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
APEC1621I NCT03526250 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
APEC1621J NCT03698994 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
APEC1621SC NCT03155620 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol